For example, the Giant Mine in Canada processed substantial amounts of arsenopyrite-contaminated gold ores. References
External links
"Arsenic trioxide". Drug Information Portal. U.S. National Library of Medicine. Case Studies in Environmental Medicine: Arsenic Toxicity
"Arsenic and Arsenic Compounds". Summaries & Evaluations. International Agency for Research on Cancer (IARC). February 1998.
International Chemical Safety Card 0378
Safety Data Sheet from American Elements
NIOSH Pocket Guide to Chemical Hazards
NTP Report on Carcinogens – Inorganic Arsenic Compounds
Institut national de recherche et de sécurité (1989). "Trioxyde darsenic." Fiche toxicologique n° 89. Paris:INRS. (in French)
Naxitamab, sold under the brand name Danyelza, is an anti-cancer medication. It is a monoclonal antibody used in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for people one year of age and older with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow demonstrating a partial response, minor response, or stable disease to prior therapy.The most common adverse reactions include infusion-related reactions, pain, tachycardia (fast heart beats), vomiting, cough, nausea, diarrhea, decreased appetite, hypertension, fatigue, erythema multiforme, peripheral neuropathy, urticaria, pyrexia, headache, injection site reaction, edema, anxiety, localized edema, and irritability.The U.S. Food and Drug Administration (FDA) granted the application for naxitamab priority review, breakthrough therapy, and, orphan drug designations. The FDA issued a priority review voucher for this rare pediatric disease product application and was later granted a priority approval. Medical uses
Naxitamab is used in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) to treat people one year of age and older with high-risk neuroblastoma in bone or bone marrow whose tumor did not respond to or has come back after previous treatments and has shown a partial response, minor response, or stable disease to prior therapy. History
The application for naxitamab was approved based on two clinical trials (Trial 1/NCT03363373 and Trial 2/NCT01757626) of 97 participants with high-risk neuroblastoma in bone or bone marrow. The trials were conducted at four centers in the United States and in Spain. Both trials enrolled participants who were previously treated for high-risk neuroblastoma in the bone or bone marrow.